

## Evidence Based Herbal Medicine and Mental Health

Hajiaghaee R (Ph.D.)<sup>1</sup>, Akhondzadeh S (Ph.D.)<sup>2\*</sup>

1- Pharmacognosy & Pharmaceutics Department of Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran

2- Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran

\* Corresponding author: Psychiatric Research Center, Roozbeh Hospital, South Kargar Street, Tehran 13337, Iran

Tel: +98-21-88281866, Fax: +98-21-55419113

Email: s.akhond@neda.net

**Received:** 21 Aug. 2012

**Accepted:** 16 Nov. 2012

### Abstract

Many cultures have developed folk herbal remedies for various symptoms of mental illness. An evidence base now is being developed for some of these “alternative” herbal remedies. There has been an increase in the number and proportion of clinical trials of complementary medicine, which suggests a trend toward an evidence-based approach. This review presents the scientific information regarding herbal medicine with evidence based approaches for saffron.

**Keywords:** *Crocus sativus*, Evidence Based Herbal Medicine, Mental health



## Introduction

Complementary medicine are interventions that are not widely taught in medical schools and are not part of the usual arsenal of treatments and medications recommended and prescribed by physicians and available in hospitals. Use of Complementary medicine is dependent, not on dissatisfaction with conventional medicine as it is most commonly used in association with conventional medicine, but on philosophical orientations towards health and life [1]. A vast quantity of information of varying quality exists in the media and on the internet. There are concerns, however, that the media and internet provide too rosy a picture of complementary medicine and downplay adverse reactions to complementary medicine, which can be dangerous and potentially fatal. These factors suggest that significant improvements need to be made to knowledge translation mechanisms for the public, healthcare professionals, and policy makers. The response of the medical and scientific community has been an increasing interest in complementary medicine issues [1]. There has been an increase in the number and proportion of clinical trials of complementary medicine, which suggests a trend toward an evidence-based approach. One of main branches of complementary medicine, is herbal medicine. Herbal medicine has seen a growth in scientifically referenced texts in the past twenty years. However, herbal medicines are interventions that are not widely taught in medical schools and are not part of the usual arsenal of treatments and medications recommended and prescribed by physicians

and available in hospitals. Nevertheless, many people using herbal medicines find the health care alternatives are more congruent with their own values, beliefs and philosophical orientations toward health and life. Similarly, it seems likely that many people feel that herbal medicines are empowering by allowing them to treat themselves without seeing a physician. The danger is that, many people believe that herbal medicines have no toxicity problems or even side effects. In addition, they are not aware of many possible interactions of herbal medicine with concurrent prescribed medications [1].

Herbal medicines include a range of pharmacologically active compounds: in some cases it is not well understood which ingredients are important for a therapeutic effect. The supporters of herbal medicine believe that isolated ingredients in the majority of cases have weaker clinical effects than whole plant extract, a claim that would obviously require proof in each case. Generalizations about the efficacy of herbal medicines are clearly not possible. Each one needs systematic research including a variety of animal studies and also randomized clinical trials. Indeed, clinical trials of herbal medicines are feasible much in the same way as for other drugs [1]. Numerous randomized clinical trials of herbal medicines have been published and systematic review and meta-analyses of these studies have been available. Many of today's synthetic drugs originated from the plant kingdom, and only about two centuries ago the major pharmacopoeias were



dominated by herbal drugs. It has been reported that most patients with a mental disorder sought herbal medicine treatment for somatic problems rather than for their mental and emotional symptoms and the best example is somatic symptoms of depression [1].

Physicians need to understand the biochemical and evidential bases for the use of herbs and nutrients to diagnose and treat patients safely and effectively, to avoid interactions with standard medications, and to provide patients with the benefits of alternative treatments [1]. This review will present saffron as example for evidence based herbal medicine.

### **Saffron (*Crocus sativus*)**

Saffron is the world's most expensive spice, derived from the flower of *Crocus sativus*. Each saffron crocus grows to 20 – 30 cm and bears up to four flowers, each with three vivid crimson stigmas [1]. Indeed, it is a Persian herb with a history as long as the Persian Empire itself. Iran, the world's largest producer of saffron has been investing in research into saffron's potential medicinal uses.

### **Depression**

To date, five published randomized controlled trials have been published about effects of saffron on depression. The first evidence-based study on this subject was published in 2004 showing that saffron was as efficacious as imipramine in the short-term treatment of mild to moderate depression in adults [2]. Importantly, saffron was more tolerable than imipramine (which often causes

anticholinergic side effects). Subsequently, saffron was compared to placebo in a six-week randomized controlled trial of 40 adult patients with mild to moderate depression. Saffron resulted in about 12-point reduction on Hamilton depression rating scale (HDRS) compared with only five points seen with the placebo. Tolerability profile of saffron was similar to the placebo [3]. Later, several studies provided evidence for antidepressant effects of different *Crocus sativus* L. constituents compared with both placebo and fluoxetine. Both petal and stigma of *Crocus sativus* L. have shown beneficial effects for treatment of depression [3, 4]. The mechanism of action of antidepressant effects of saffron is not clearly understood. However, reuptake inhibition of monoamines, NMDA antagonism, and possibly improved BDNF signaling might be implicated in its mechanism of action [5, 6]. In summary, saffron extract with a dose of 20 mg twice daily, seems to be as efficacious and tolerable as fluoxetine for short-term treatment of mild to moderate depression [7]. Long-term studies for comparison of relapse rates are still lacking. Interestingly, saffron does not cause sexual side effects generally associated with fluoxetine use; indeed it can prevent or treat some aspects of fluoxetine induced sexual impairment [8].

### **Anxiety and sleep problems**

Published studies on anti-anxiety effects of saffron are limited to animal experiments [9, 10]. Activation of GABA-A receptors might explain the anxiolytic effects of saffron [11].

Animal studies also demonstrated improvement of non-rapid eye movement (non-REM) sleep following safranal and crocin administration in mice [12, 13]. Safranal enhanced non-REM sleep probably by activation of the sleep center in the ventrolateral preoptic nucleus and the inhibition of the histaminergic tuberomammillary nuclei [12].

### **Reproductive and sexual problems**

The only clinical trial on the effect of saffron on premenstrual syndrome showed that use of saffron 15 mg twice daily for two menstrual cycles was significantly more effective than placebo in improvement of depression and premenstrual daily symptoms [14]. In an open label study, saffron odor reduced cortisol levels and anxiety, and increased estrogen levels in both follicular and luteal phases [15]. A clinical trial compared the effect of placebo, mefenamic acid, and an herbal drug (composed of saffron, celery seed, and anise) on primary dysmenorrhea in young women. After two or three cycles, patients in the herbal drug group reported significantly lower pain scores than patients in other groups [16].

Traditionally, saffron was thought to improve sexual functioning. From an evidence-based point of view, *Crocus sativus* L. and its constituents improved all components of sexual function in male rats [17]. Administration of high dose of saffron (200 mg/day) for ten days to 20 patients with erectile dysfunction, significantly improved nocturnal penile tumescence as well as score

on the international index of erectile function (IIEF) questionnaire [18]. In a recent study, saffron 15 mg twice daily was used to treat fluoxetine-induced sexual dysfunction in male patients with major depression. The authors found significant improvement in the erectile function and intercourse satisfaction (but not desire and orgasmic function) domains of IIEF in the saffron group. Sixty percent of patients in the saffron group compared with only 7% of patients in the placebo group achieved normal erectile function at the end of the study [8]. In a parallel safety study on the same patients, saffron did not affect liver, kidney, and blood tests. Moreover, frequency of adverse events in the saffron group was similar to that of the placebo [19]. In a similar study which was carried out on women with fluoxetine-associated sexual dysfunction, saffron resulted in improvement of arousal, pain and lubrication domains while it did not affect satisfaction, orgasm, and desire (under review).

### **Neurotoxicity and Alzheimer's disease**

Several constituents of saffron including safranal, crocin, crocetin, and carotenoids have shown neuroprotective properties in animal models of ischemic, oxidative, traumatic, and inflammatory brain injury. Among several constituent of saffron, crocin showed the highest neuroprotective activity in one study. The neuroprotective activity of crocin is probably secondary to enhancement of glutathione (GSH) synthesis through increasing expression of gamma-glutamylcysteinyl synthase (gamma-GCS). In



a hemi-parkinsonian mouse model, crocetin pretreatment preserved levels of GSH, dopamine, and activity of antioxidant enzymes, and protected neurons of substantia nigra [21].

*Crocus sativus* L. is increasingly being studied as a memory enhancer. Saffron can attenuate the deleterious effect of ethanol on memory registration and retrieval, and prevent ethanol-induced inhibition of hippocampal long-term potentiation [23, 24]. Crocin seems to be involved in spatial memory and recognition and blocked scopolamine-induced performance deficits in the step-through passive avoidance and radial water maze tests [25, 26]. Saffron showed similar protective effects on recognition and spatial memory in chronic stress and hypoperfusion models of memory impairment [27, 28].

In an animal model of AD induced by intraventricular injection of streptozocin, Khalili et al. showed that administration of crocin resulted in significantly better results in passive avoidance test [29]. In a 16-week placebo-controlled study, 46 patients with mild to moderate AD were assigned to saffron 15 mg twice daily or placebo. At the end of the trial, saffron was associated with a significantly better outcome on cognitive function than placebo. Importantly, tolerability of saffron was similar to placebo [30]. In a 22-week donepezil-controlled study, saffron 15 mg twice daily was compared to donepezil 5 mg twice daily. Saffron was as efficacious as donepezil, but was associated with lower frequency of side effects than donepezil [31].

The mechanism of action of cognitive enhancement by saffron merits further consideration. Saffron seems to both antagonize glutamatergic activity on NMDA receptors (similar to memantine) [5,32,33] and to inhibit acetylcholinesterases (similar to donepezil) [34]. AD is associated with inflammatory activation in the brain as shown by several studies. Saffron (particularly its crocin and crocetin constituents) effectively inhibited glial activation induced by interferon and amyloid beta, and reduced levels of several inflammatory markers in the rat brain [37].

#### **Adverse effects and toxicity**

In a double-blind, placebo-controlled study, three groups of volunteers received placebo, 200 mg/day, or 400 mg/day saffron tablets for one week. High dose saffron reduced systolic blood pressure and mean arterial pressures significantly. Moreover, saffron slightly reduced or increased some hematological and biochemical parameters (hemoglobin, hematocrit, platelets, sodium, blood urea nitrogen and creatinine). None of the mentioned changes had clinical significance [39]. It should be emphasized that with the doses used in the clinical setting (usually less than 100 and often less than 60 mg/day) saffron is generally no less tolerable than placebo. A case of proven anaphylaxis following eating rice cooked with saffron has been reported. The authors recommended that saffron should be regarded as an allergen when investigating the causes of allergies.

## References

1. Akhondzadeh S. Herbal medicine in the treatment of psychiatric and neurological Disorders. In: L'Abate L. *Low Cost Approaches to Promote Physical and Mental Health: Theory Research and Practice*. New York. 2007, pp: 119 - 38.
2. Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH and Khalighi-Cigaroudi F. Comparison of *Crocus sativus* L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. *BMC Comp. Alt. Med.* 2004; 4: 12.
3. Akhondzadeh S, Tamacebi-pour N, Noorbala AA, Amini H, Fallah Pour H, Jamshidi AH and Khani M. *Crocus sativus* L. in the treatment of mild to moderate depression: A double-blind, randomized and placebo controlled trial. *Phytother. Res.* 2005; 19: 25 - 9.
4. Hosseinzadeh H and Sadeghnia HR. Safranal, a constituent of *Crocus sativus* (saffron), attenuated cerebral ischemia induced oxidative damage in rat hippocampus. *J. Pharm. Pharm. Sci.* 2005; 8 (3): 394 - 9.
5. Berger F, Hensel A, Nieber K. Saffron extract and trans-crocin inhibit glutamatergic synaptic transmission in rat cortical brain slices. *Neuroscience* 2011; 180: 238 - 47.
6. Shimizu Y, Inoue E, Motegi J, Nonaka K, Noguchi T, Shoji M, Sudoh K. Pharmacological studies of Nougassei, a crude drug containing red ginseng, polygala root, saffron, antelope horn and agarwood - Antidepressant-like effect in the mouse forced swimming test. *Jap. Pharmacol. Therapeutics* 2011; 39 (6): 587 - 94.
7. Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of *Crocus sativus* L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. *Prog Neuropsychopharmacol. Biol. Psychiatry* 2007; 31: 439 - 42.
8. Modabbernia A, Sohrabi H, Nasehi AA, , Raisi F, Saroukhani S, Jamshidi A, Tabrizi M, Ashrafi M, Akhondzadeh S. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. *Psychopharmacol.* 2012; 223 (4): 381 - 8.
9. Pitsikas N, Boultadakis A, Georgiadou G, Tarantilis PA, Sakellaridis N. Effects of the active constituents of *Crocus sativus* L., crocins, in an animal model of anxiety. *Phytomedicine* 2008; 15 (12): 1135 - 9.
10. Hosseinzadeh H, Noraei NB. Anxiolytic and hypnotic effect of *Crocus sativus* aqueous extract and its constituents, crocin and safranal, in mice. *Phytother Res.* 2009; 23 (6): 768 - 4.
11. Hosseinzadeh H, Sadeghnia HR. Protective effect of safranal on pentylenetetrazol-induced seizures in the rat: involvement of GABAergic and opioids systems. *Phytomedicine* 2005; 14 (4): 256 - 62.
12. Masaki M, Aritake K, Tanaka H, Shoyama Y, Huang ZL, Urade Y. Crocin promotes non-rapid eye movement sleep in mice. *Mol. Nutr.*



*Food Res.* 2012; 56 (2): 304 - 8.

**13.** Akhondzadeh S, Abbasi SH. Herbal medicine in the treatment of Alzheimer's disease. *Am. J. Alzheimers Dis. Other Demen.* 2006; 21 (2): 113 - 8.

**14.** Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A, Rahmanpour H, Zarrinara AR, Akhondzadeh S. *Crocus sativus* L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. *BJOG.* 2008; 115 (4): 515 - 9.

**15.** Nahid K, Fariborz M, Ataolah G, Solokian S. The effect of an Iranian herbal drug on primary dysmenorrhea: a clinical controlled trial. *J. Midwifery Womens Health.* 2009; 54 (5): 401 - 4.

**16.** Hosseinzadeh H, Ziaee T, Sadeghi A. The effect of saffron, *Crocus sativus* stigma, extract and its constituents, safranal and crocin on sexual behaviors in normal male rats. *Phytomedicine* 2008; 15 (6 - 7): 491 - 5.

**17.** Shamsa A, Hosseinzadeh H, Molaei M, Shakeri MT, Rajabi O. Evaluation of *Crocus sativus* L. (saffron) on male erectile dysfunction: a pilot study. *Phytomedicine* 2009; 16 (8): 690 - 3.

**18.** Mansoori P, Akhondzadeh S, Raisi F, Ghaeli P, Jamshidi AH, Nasehi AA, Sohrabi H, Saroukhani S. A randomized, double-blind, placebo - controlled study of safety of the adjunctive saffron on sexual dysfunction induced by a selective serotonin reuptake inhibitor. *J. Medicinal Plants* 2001; 10 (37): 121 - 30.

**19.** Premkumar K, Abraham SK, Santhiya ST, Ramesh A. Protective effects of saffron (*Crocus sativus* Linn.) on genotoxins-induced

oxidative stress in Swiss albino mice. *Phytother Res.* 2003; 17 (6): 614 - 7.

**20.** Ahmad A, Ansari SMA, Ahmad M, Saleem S, Yousuf S, Hoda MN, Islam F. Neuroprotection by crocetin in a hemiparkinsonian rat model. *Pharmacol Biochem Behav* 2005; 81 (4): 805 - 13.

**21.** Zheng YQ, Liu JX, Wang JN, Xu L. Effects of crocin on reperfusion-induced oxidative/nitrative injury to cerebral microvessels after global cerebral ischemia. *Brain Res.* 2007; 1138: 86 - 94.

**22.** Zhang Y, Shoyama Y, Sugiura M, Saito H. Effects of *Crocus sativus* L. on the ethanol-induced impairment of passive avoidance performances in mice. *Biol. Pharm. Bull.* 1994; 17 (2): 217 - 21.

**23.** Abe K, Saito H. Effects of saffron extract and its constituent crocin on learning behaviour and long-term potentiation. *Phytother Res.* 2000; 14 (3): 149 - 52.

**24.** Pitsikas N, Sakellaridis N. *Crocus sativus* L. extracts antagonize memory impairments in different behavioural tasks in the rat. *Behav Brain Res.* 2006; 173 (1): 112 - 5.

**25.** Pitsikas N, Zisopoulou S, Tarantilis PA, Kanakis CD, Polissiou MG, Sakellaridis N. Effects of the active constituents of *Crocus sativus* L., crocins on recognition and spatial rats' memory. *Behav. Brain Res.* 2007; 183 (2): 141 - 6.

**26.** Ghadrdoost, B, Vafaei AA, Rashidy-Pour A, Hajisoltani R, Bandegi AR, Motamedi F, Haghghi S, Sameni HR, Pahlvan S. Protective effects of saffron extract and its active constituent crocin against oxidative stress and spatial learning and memory deficits induced



- by chronic stress in rats. *Eur. J. Pharmacol.* 2011; 667 (1 -3): 222 - 9.
- 27.** Hosseinzadeh H, Sadeghnia HR, Ghaeni FA, Motamedshariaty VS, Mohajeri SA. Effects of saffron (*Crocus sativus* L.) and its active constituent, crocin, on recognition and spatial memory after chronic cerebral hypoperfusion in rats. *Phytother Res.* 2012; 26 (3): 381 - 6.
- 28.** Khalili M, Hamzeh F. Effects of active constituents of *Crocus sativus* L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats. *Iran Biomed. J.* 2010; 14: (1 - 2): 59 - 65.
- 29.** Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSH, Yousefi MH, Alimardani R, Jamshidi A, Zare F, Moradi A. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. *J. Clin. Pharm. Ther.* 2010; 35: 581 - 8.
- 30.** Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SSH, Yousefi MH, Alimardani R, Jamshidi A, Rezazadeh SA, Yousefi A, Zare F, Moradi A, Vossoughi A. A 22-week, multicenter, randomized, double blind controlled trial of *Crocus sativus* in the treatment of mild-to-moderate Alzheimer's disease. *Psychopharmacology (Berl)* 2010; 207: 637 - 43.
- 31.** Lechtenberg M, Schepmann D, Niehues M, Hellenbrand N, Wunsch B, Hensel A. Quality and functionality of saffron: quality control, species assortment and affinity of extract and isolated saffron compounds to NMDA and sigma1 (sigma-1) receptors. *Planta Med.* 2008; 74 (7): 764 - 72.
- 32.** Ohno Y, Nakanishi T, Umigai N, Tsuruma K, Shimazawa M, Hara H. Oral administration of crocetin prevents inner retinal damage induced by N-methyl-d-aspartate in mice. *Eur. J. Pharmacol.* 2012; 690 (1 - 3): 84 - 9.
- 33.** Geromichalos GD, Lamari FN, Papandreou MA, Trafalis DT, Margarity M, Papageorgiou A, Sinakos Z. Saffron as a source of novel acetylcholinesterase inhibitors: molecular docking and in vitro enzymatic studies. *J. Agric. Food Chem.* 2012; 60 (24): 6131 - 8.
- 34.** Akhondzadeh S, Stone TW. Interaction between adenosine and GABAA receptors on hippocampal neurones. *Brain Res.* 1994; 665 (2): 229 - 36.
- 35.** Akhondzadeh S. Hippocampal synaptic plasticity and cognition. *J. Clin. Pharm. Ther.* 1999; 24 (4): 241 - 8.
- 36.** Akhondzadeh S. The 5-HT hypothesis of schizophrenia. *IDrugs* 2001; 4 (3): 295 - 300.
- 37.** Nam KN, Park YM, Jung HJ, Lee JY, Min BD, Park SU, Jung WS, Cho KH, Park JH, Kang L, Hong JW, Lee EH. Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. *Eur. J. Pharmacol.* 2010; 648 (1 - 3): 110 - 6.
- 38.** Modaghegh MH, Shahabian M, Esmaeili HA, Rajbai O, Hosseinzadeh H. Safety evaluation of saffron (*Crocus sativus*) tablets in healthy volunteers. *Phytomedicine* 2008; 15: (12): 1032 - 7.
- 39.** Wuthrich B, Schmid-Grendelmeyer P, Lundberg M. Anaphylaxis to saffron. *Allergy* 1997; 52 (4): 476 - 7.

